Drug Pricing Policy Summit: Patients Redefining Health Care Backgrounder

Join patient groups and health care stakeholders from across Canada to explore a new vision for health care in Canada based on a patient-defined Value-Based Health Care (VBHC) model.

Building on the 2017 Summit where VBHC was introduced to participants, the 2018 Summit will dive deeper into VBHC within the context of drug treatment and will build a work plan for VBHC in Canada, led by patients, caregivers and their allies.

VBHC is a patient-centered approach to health care with a goal of improved value for patients, measured by the quality of health outcomes per dollar spent to achieve those outcomes.

Using relevant examples of patients’ experiences with the Canadian health care system across a variety of medical conditions, demographic and geographical settings, and considering various social determinants of health, this year’s Summit breakout groups will apply VBHC principles and ideas from a patient’s perspective to establish a practical and actionable work plan. Work plans will consider optimizing patient experiences and outcomes and reducing health system inefficiencies. Breakout groups will identify existing health care stakeholders who can play a part in moving the work plan forward as well as opportunities to address areas of the work plan where there is unmet support. International and Canadian VBHC leaders and early adopters, Summit Working Groups and health system experts will both inspire and contribute to the formation of the work plans over the two days.

Background

The 3rd annual Drug Pricing Policy Summit: Patients Redefining Health Care builds on the 2016 and 2017 Summits which provided an unprecedented opportunity for patients, caregivers and patient representatives from diverse disease and disability groups to come together to discuss a shared vision for health care in Canada.

The objective of the Summits is to examine and constructively critique existing public regulations, policies and practices at a national and provincial/territorial level, and within the private sector. These regulations, policies and practices directly and indirectly affect the price, cost and coverage of drugs in Canada and by extension, have an impact on access to needed therapies and treatments for Canadians, policies and practices on the work they do. The Summits also share the perspectives of numerous health care stakeholders about the impact of these regulations, policies and practices on their work.

Working Groups formed during Summits work throughout the year to identify further steps and action items, intended to lead to short- and long-term tangible strategies, that will shape drug pricing policy in Canada and make related processes more accessible to, and inclusive of, patient and caregiver groups.